Randomised phase III study of alisertib or investigator's choice (selected singe agent) in patients with relapsed or refractory peripheral T-cell lymphoma

Autor: O'connor, O, Özcan, M, Jacobsen, E, Roncero Vidal, JM, Trotman, J, Demeter, J, Masszi, T, Pereira, J, Ramchandren, R, Beaven, A, Caballero Barringon, D, Horwitz, S, Lennard, A, Turgut, M, Hamerschlak, N, d'Amore, Francesco Annibale, Foss, F, Kim, WS, Leonard, JP, Zinzani, PL, Chiattone, CS, His, ED, Liu, H, Sheldon-Waniga, E, Dansky Ullmann, C, Leonard, EJ, Shustov, A

Publikováno v: O'connor, O, Özcan, M, Jacobsen, E, Roncero Vidal, JM, Trotman, J, Demeter, J, Masszi, T, Pereira, J, Ramchandren, R, Beaven, A, Caballero Barringon, D, Horwitz, S, Lennard, A, Turgut, M, Hamerschlak, N, d'Amore, F A, Foss, F, Kim, WS, Leonard, JP, Zinzani, PL, Chiattone, CS, His, ED, Liu, H, Sheldon-Waniga, E, Dansky Ullmann, C, Leonard, EJ & Shustov, A 2017, ' Randomised phase III study of alisertib or investigator's choice (selected singe agent) in patients with relapsed or refractory peripheral T-cell lymphoma. ', Lancet Oncology .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::b0efe25f75509b7a2e9ec6fe67e7a5fc
https://pure.au.dk/portal/da/publications/randomised-phase-iii-study-of-alisertib-or-investigators-choice-selected-singe-agent-in-patients-with-relapsed-or-refractory-peripheral-tcell-lymphoma(7f9b613c-0fc5-49fa-a97b-f368d4f8af0d).html

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.

Autor: Witzig T; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN., Sokol L; Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Kim WS; Division of Hematology-Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, South Korea., de la Cruz Vicente F; Department of Hematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Martín García-Sancho A; Hematology Department, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación Biomédica en Red - Cáncer (CIBERONC), Salamanca, Spain., Advani R; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA., Roncero Vidal JM; Servei Hematologia ICO Girona, Hospital Universitari de Girona Dr Josep Trueta, Catalunya, Spain., de Oña Navarrete R; Hematology Department, MD Anderson Cancer Center, Madrid, Spain., Marín-Niebla A; Department of Hematology, Vall D'Hebron Institute of Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Rodriguez Izquierdo A; Servicio de Hematología y Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain., Terol MJ; Hospital Clínico Universitario de Valencia, Valencia, Spain., Domingo-Domenech E; Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain., Saunders A; Kura Oncology Inc, Boston, MA., Bendris N; Kura Oncology Inc, Boston, MA., Mackey J; Kura Oncology Inc, Boston, MA., Leoni M; Kura Oncology Inc, Boston, MA., Foss F; Division of Hematology, Yale University School of Medicine, New Haven, CT.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 10; Vol. 8 (17), pp. 4581-4592.

Follicular dendritic cell tumor in the context of a Castleman disease in a patient with Diffuse Large B Cell Lymphoma: Diagnosis and follow-up with ¹⁸ F-FDG PET/CT.

Autor: Negre Busó M; Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, Spain. Electronic address: montserrat.negre.idi@gencat.cat., Balliu Collgrós E; Servei de Radiologia-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, Spain., Ferran Sureda N; Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, Spain., Velasco Nuño M; Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, Spain., Roncero Vidal JM; Servei Hematologia-ICO Girona, Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, Spain., Rubió Rodríguez A; Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Catalunya, Spain.

Publikováno v: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2021 Sep-Oct; Vol. 40 (5), pp. 322-324. Date of Electronic Publication: 2020 Sep 03.